Sanofi's New Gaucher Drug Cost Doesn't Add Up For NICE
Sanofi and UK HTA body NICE have come up with drastically different numbers for how much new oral Gaucher disease treatment Cerdelga will end up costing per patient. The result? Despite being the first oral treatment option for patients, NICE doesn't think Cerdelga is worth it.
Register for our free email digests: